Xencor Inc Forecasted to Earn FY2019 Earnings of ($2.12) Per Share (XNCR)

Xencor Inc (NASDAQ:XNCR) – Equities research analysts at Cantor Fitzgerald issued their FY2019 earnings estimates for Xencor in a note issued to investors on Monday. Cantor Fitzgerald analyst W. Tanner anticipates that the biopharmaceutical company will post earnings of ($2.12) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $33.00 price target on the stock.

Several other brokerages have also commented on XNCR. ValuEngine lowered Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Canaccord Genuity set a $36.00 price target on Xencor and gave the company a “buy” rating in a research note on Monday, October 23rd. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 price objective on shares of Xencor in a research note on Sunday, November 12th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $30.80.

Shares of Xencor (NASDAQ XNCR) traded up $0.24 during mid-day trading on Wednesday, reaching $23.16. The company had a trading volume of 111,685 shares, compared to its average volume of 143,933. The firm has a market cap of $1,090.00, a price-to-earnings ratio of -22.93 and a beta of 2.09. Xencor has a twelve month low of $18.55 and a twelve month high of $28.64.

Hedge funds have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can raised its position in shares of Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 4,005 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Xencor by 62.6% during the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 3,252 shares during the last quarter. Legal & General Group Plc raised its position in shares of Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 385 shares during the last quarter. Principal Financial Group Inc. bought a new stake in shares of Xencor during the third quarter worth $201,000. Finally, Citadel Advisors LLC bought a new stake in shares of Xencor during the second quarter worth $224,000. Institutional investors own 77.50% of the company’s stock.

In other news, major shareholder John S. Stafford III bought 24,653 shares of the company’s stock in a transaction dated Wednesday, October 25th. The stock was bought at an average price of $20.01 per share, for a total transaction of $493,306.53. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder John S. Stafford III bought 9,215 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were purchased at an average price of $20.76 per share, with a total value of $191,303.40. The disclosure for this purchase can be found here. In the last three months, insiders acquired 278,535 shares of company stock worth $5,526,936. Insiders own 4.03% of the company’s stock.

WARNING: “Xencor Inc Forecasted to Earn FY2019 Earnings of ($2.12) Per Share (XNCR)” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2018/01/05/xencor-inc-forecasted-to-earn-fy2019-earnings-of-2-12-per-share-xncr.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply